David W Miller, MD | |
1906 Blake Ave, Suite 302, Glenwood Springs, CO 81601-4227 | |
(970) 384-6770 | |
(970) 384-6765 |
Full Name | David W Miller |
---|---|
Gender | Male |
Speciality | Neurological Surgery |
Location | 1906 Blake Ave, Glenwood Springs, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497764195 | NPI | - | NPPES |
31774016 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | 38595 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
David W Miller, MD 1906 Blake Ave, Suite 302, Glenwood Springs, CO 81601-4227 Ph: (970) 384-6770 | David W Miller, MD 1906 Blake Ave, Suite 302, Glenwood Springs, CO 81601-4227 Ph: (970) 384-6770 |
News Archive
As COVID-19-related social isolation and distancing make it increasingly difficult for people with neurological conditions to access routine medical care, the crisis is transforming the way care is being delivered to these vulnerable individuals, according to neurology service providers.
smoking rate has plummeted since a comprehensive program against smoking was launched in 2002, according to findings issued today in the national Centers for Disease Control and Prevention?s Morbidity and Mortality Weekly Report (MMWR).
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
Rainer Kube and his working group report in the current issue of Deutsches -rzteblatt International on new treatment strategies in patients with colon cancer.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
› Verified 1 days ago